These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1755767)

  • 1. Preventing breast cancer: is it possible?
    Ingram D
    Aust N Z J Surg; 1991 Dec; 61(12):884-91. PubMed ID: 1755767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for the primary prevention of breast cancer.
    Bernstein L; Ross RK; Henderson BE
    Am J Epidemiol; 1992 Jan; 135(2):142-52. PubMed ID: 1311141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LHRH agonists and the prevention of breast and ovarian cancer.
    Pike MC; Ross RK; Lobo RA; Key TJ; Potts M; Henderson BE
    Br J Cancer; 1989 Jul; 60(1):142-8. PubMed ID: 2679844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
    ; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
    Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
    J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers.
    Emons G; Schally AV
    Hum Reprod; 1994 Jul; 9(7):1364-79. PubMed ID: 7962452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phyto-oestrogens and breast cancer chemoprevention.
    Limer JL; Speirs V
    Breast Cancer Res; 2004; 6(3):119-27. PubMed ID: 15084232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An appraisal of strategies to reduce the incidence of breast cancer.
    Jordan VG; Morrow M
    Stem Cells; 1993 Jul; 11(4):252-62. PubMed ID: 8401248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprevention of breast cancer.
    Bonte J
    Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():141-5. PubMed ID: 8298444
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of breast cancer in premenopausal women.
    Love RR
    J Natl Cancer Inst Monogr; 1994; (16):61-5. PubMed ID: 7999471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevention of breast cancer through reduced ovarian steroid exposure.
    Spicer DV; Pike MC
    Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of breast cancer.
    Hackshaw A
    Expert Opin Pharmacother; 2009 Nov; 10(16):2633-9. PubMed ID: 19874248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis approach to a-symptomatic post-menopausal women: breast cancer.
    Aguas F; Martins A; Gomes TP; de Sousa M; Silva DP;
    Maturitas; 2005 Nov; 52 Suppl 1():S23-31. PubMed ID: 16126355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist.
    Miller WR; Scott WN; Morris R; Fraser HM; Sharpe RM
    Nature; 1985 Jan 17-23; 313(5999):231-3. PubMed ID: 2982100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of GnRH analogues in early and advanced breast carcinomas].
    Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
    Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Emens LA; Davidson NE
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.